Background: Interstitial fibrosis (IF), tubular atrophy (TA) and interstitial inflammation (II) are known determinants of progression of renal disease. Standardized quantification of these features could add value to current classification of glomerulopathies. Methods: We studied 315 participants in the Nephrotic Syndrome Study Network (NEPTUNE) study, including biopsy-proven minimal change disease (MCD = 98), focal segmental glomerulosclerosis (FSGS = 121), membranous nephropathy (MN = 59) and IgA nephropathy (IgAN = 37). Cortical IF, TA and II were quantified (%) on digitized whole-slide biopsy images, by five pathologists with high inter-reader agreement (intra-class correlation coefficient >0.8). Tubulointerstitial messenger RNA expression was measured in a subset of patients. Multivariable Cox proportional hazards models were fit to assess association of IF with the composite of 40% decline in estimated glomerular filtration rate (eGFR) and end-stage renal disease (ESRD) and separately as well, and with complete remission (CR) of proteinuria. Results: IF was highly correlated with TA (P < 0.001) and II (P < 0.001). Median IF varied by diagnosis: FSGS 17, IgAN 21, MN 7, MCD 1 (P < 0.001). IF was strongly correlated with baseline eGFR (P < 0.001) and proteinuria (P = 0.002). After adjusting for clinical pathologic diagnosis, age, race, global glomerulosclerosis, baseline proteinuria, eGFR and medications, each 10% increase in IF was associated with a hazard ratio of 1.29 (P < 0.03) for ESRD/40% eGFR decline, but was not significantly associated with CR. A total of 981 genes were significantly correlated with IF (|r| > 0.4, false discovery rate (FDR) < 0.01), including upstream regulators such as tumor necrosis factor, interferon gamma (IFN-gamma), and transforming growth factor beta 1 (TGF-B1), and signaling pathways for antigen presentation and hepatic fibrosis. Conclusions: The degree of IF is associated with risk of eGFR decline across different types of proteinuric glomerulopathy, correlates with inflammatory and fibrotic gene expression, and may have predictive value in assessing risk of progression.
Background: Interstitial fibrosis (IF), tubular atrophy (TA) and interstitial inflammation (II) are known determinants of progression of renal disease. Standardized quantification of these features could add value to current classification of glomerulopathies. Methods: We studied 315 participants in the Nephrotic Syndrome Study Network (NEPTUNE) study, including biopsy-proven minimal change disease (MCD = 98), focal segmental glomerulosclerosis (FSGS = 121), membranous nephropathy (MN = 59) and IgA nephropathy (IgAN = 37). Cortical IF, TA and II were quantified (%) on digitized whole-slide biopsy images, by five pathologists with high inter-reader agreement (intra-class correlation coefficient >0.8). Tubulointerstitial messenger RNA expression was measured in a subset of patients. Multivariable Cox proportional hazards models were fit to assess association of IF with the composite of 40% decline in estimated glomerular filtration rate (eGFR) and end-stage renal disease (ESRD) and separately as well, and with complete remission (CR) of proteinuria. Results: IF was highly correlated with TA (P < 0.001) and II (P < 0.001). Median IF varied by diagnosis: FSGS 17, IgAN 21, MN 7, MCD 1 (P < 0.001). IF was strongly correlated with baseline eGFR (P < 0.001) and proteinuria (P = 0.002). After adjusting for clinical pathologic diagnosis, age, race, global glomerulosclerosis, baseline proteinuria, eGFR and medications, each 10% increase in IF was associated with a hazard ratio of 1.29 (P < 0.03) for ESRD/40% eGFR decline, but was not significantly associated with CR. A total of 981 genes were significantly correlated with IF (|r| > 0.4, false discovery rate (FDR) < 0.01), including upstream regulators such as tumor necrosis factor, interferon gamma (IFN-gamma), and transforming growth factor beta 1 (TGF-B1), and signaling pathways for antigen presentation and hepatic fibrosis. Conclusions: The degree of IF is associated with risk of eGFR decline across different types of proteinuric glomerulopathy, correlates with inflammatory and fibrotic gene expression, and may have predictive value in assessing risk of progression.
Authors: Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2015-11-13 Impact factor: 10.121
Authors: Sean J Barbour; Gabriela Espino-Hernandez; Heather N Reich; Rosanna Coppo; Ian S D Roberts; John Feehally; Andrew M Herzenberg; Daniel C Cattran Journal: Kidney Int Date: 2016-01 Impact factor: 10.612
Authors: Jennifer Y Lai; Jinghui Luo; Christopher O'Connor; Xiaohong Jing; Viji Nair; Wenjun Ju; Ann Randolph; Iddo Z Ben-Dov; Regina N Matar; Daniel Briskin; Jiri Zavadil; Robert G Nelson; Thomas Tuschl; Frank C Brosius; Matthias Kretzler; Markus Bitzer Journal: J Am Soc Nephrol Date: 2014-08-21 Impact factor: 10.121
Authors: Walter K Kremers; Aleksandar Denic; John C Lieske; Mariam P Alexander; Vidhu Kaushik; Hisham E Elsherbiny; Harini A Chakkera; Emilio D Poggio; Andrew D Rule Journal: Nephrol Dial Transplant Date: 2015-04-16 Impact factor: 5.992
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel Journal: Am J Transplant Date: 2014-02 Impact factor: 8.086
Authors: Jonathan P Troost; Howard Trachtman; Patrick H Nachman; Matthias Kretzler; Cathie Spino; Radko Komers; Sarah Tuller; Kalyani Perumal; Susan F Massengill; Elaine S Kamil; Gia Oh; David T Selewski; Patrick Gipson; Debbie S Gipson Journal: Clin J Am Soc Nephrol Date: 2017-11-22 Impact factor: 8.237
Authors: Kana N Miyata; Cynthia C Nast; Tiane Dai; Ramanath Dukkipati; Janine A LaPage; Jonathan P Troost; Leon J Schurgers; Matthias Kretzler; Sharon G Adler Journal: Exp Mol Pathol Date: 2018-07-06 Impact factor: 3.362
Authors: Peter C Grayson; Sean Eddy; Jaclyn N Taroni; Yaíma L Lightfoot; Laura Mariani; Hemang Parikh; Maja T Lindenmeyer; Wenjun Ju; Casey S Greene; Brad Godfrey; Clemens D Cohen; Jeffrey Krischer; Matthias Kretzler; Peter A Merkel Journal: Ann Rheum Dis Date: 2018-05-03 Impact factor: 19.103
Authors: Anand Srivastava; Ragnar Palsson; Arnaud D Kaze; Margaret E Chen; Polly Palacios; Venkata Sabbisetti; Rebecca A Betensky; Theodore I Steinman; Ravi I Thadhani; Gearoid M McMahon; Isaac E Stillman; Helmut G Rennke; Sushrut S Waikar Journal: J Am Soc Nephrol Date: 2018-06-04 Impact factor: 10.121